BY NADIA NTIAMOAH
The United States Food and Drug Administration (FDA) has announced a nationwide recall of several batches of levothyroxine sodium tablets after concerns emerged that the medication may contain less active ingredient than required, potentially reducing its effectiveness for patients who depend on it to manage thyroid conditions.
The affected prescription medication, distributed by Major Pharmaceuticals, is commonly used in the treatment of hypothyroidism, a condition in which the thyroid gland does not produce enough thyroid hormone. Levothyroxine may also be prescribed as part of treatment for some patients with thyroid cancer.
According to the recall information, the affected tablets have been classified as “subpotent,” meaning they may not provide the strength of medication indicated on the label. This raises concerns that patients taking the recalled tablets may not receive their prescribed dose.
The recall covers several strengths of levothyroxine sodium tablets distributed nationwide in the United States, ranging from 25 micrograms to 150 micrograms.
Among the affected 100-tablet bottles are 25 mcg tablets with lot number N02212 and a July 2026 expiration date; 50 mcg tablets with lot N02200, expiring in October 2026; and 75 mcg tablets covering lots N02172, N02296 and N02288, with expiration dates in July and December 2026.
The recall also includes 88 mcg tablets under lot N02310, expiring in January 2027; 112 mcg tablets under lot N02203, expiring in September 2026; 125 mcg tablets under lot N02266, expiring in November 2026; and 150 mcg tablets under lot N02167, which expire in July 2026.
Several 10-tablet packages are also affected.
These include 25 mcg tablets under lots N02212A, N02212B and N02212; 50 mcg tablets under lots N02200A, N02200B and N02200; and 75 mcg tablets carrying lot numbers N02172A, N02172B, N02288A, N02288B, N02172 and N02288.
The affected 10-tablet packages additionally include 125 mcg tablets carrying lot numbers N02266A, N02266B and N02266, as well as 150 mcg tablets under lots N02167A and N02167.
The FDA has classified the action as a Class II recall. Such a classification generally means use of or exposure to the affected product may cause temporary or medically reversible health consequences, while the probability of serious adverse consequences is considered remote.
The development is particularly significant because levothyroxine is intended to replace or supplement thyroid hormone. Patients prescribed the medication generally require an appropriate dose to keep their thyroid hormone levels properly controlled.
Consumers are therefore being advised to carefully examine their medication containers to determine whether the strength, National Drug Code, lot number and expiration date correspond with products covered by the recall.
However, patients should not abruptly stop taking prescribed levothyroxine solely because of the recall without first obtaining professional medical advice. Anyone who believes they have an affected product should promptly contact their pharmacist or healthcare provider for guidance and arrangements for an appropriate replacement.
Patients experiencing health concerns after taking medication covered by the recall have also been advised to seek medical attention.
The recall applies specifically to the identified levothyroxine sodium tablets distributed by Major Pharmaceuticals and should not be interpreted as a recall of every levothyroxine medication on the market.
Consumers using levothyroxine are therefore encouraged to check the manufacturer and identifying information on their prescription bottle rather than discontinuing treatment based only on the medication’s name.
